Literature DB >> 18728285

Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide.

Daniela Trisciuoglio1, Badarch Uranchimeg, John H Cardellina, Tamara L Meragelman, Shigeki Matsunaga, Nobuhiru Fusetani, Donatella Del Bufalo, Robert H Shoemaker, Giovanni Melillo.   

Abstract

BACKGROUND: Candidaspongiolide (CAN), a novel polyketide from a marine sponge, is the active component of a mixture that was found to be potently cytotoxic in the National Cancer Institute's 60-cell-line screen.
METHODS: Effects of CAN on U251 glioma and HCT116 colorectal cancer cells and on normal fibroblasts were assessed using radiolabeling studies to measure protein synthesis, clonogenic assays to measure cell survival, flow cytometry of annexin V- and propidium iodide-stained cells to measure apoptosis, and western blots in the presence or absence of specific inhibitors to assess accumulation and phosphorylation of potential downstream target proteins.
RESULTS: CAN inhibited protein synthesis and potently induced apoptosis in both U251 and HCT116 cells, the latter in part by a caspase 12-dependent pathway. For example, 25%-30% of U251 or HCT116 cells became apoptotic after 24 hours of treatment with 100 nM CAN. CAN also rapidly induced sustained phosphorylation of eukaryotic translation initiation factor-2 (eIF2)-alpha at Ser51 and of the translation elongation factor eEF2 at Thr56, which could contribute to its dose-dependent inhibition of protein synthesis. Stable expression of dominant-negative eIF2alpha was sufficient to prevent CAN-induced eIF2alpha phosphorylation and induction of apoptosis but insufficient to prevent inhibition of protein synthesis. CAN induction of eIF2alpha phosphorylation did not occur by a classic endoplasmic reticulum stress pathway. However, an inhibitor of and small-interfering RNAs to the double-stranded RNA-dependent protein kinase PKR prevented CAN-mediated eIF2alpha phosphorylation and apoptosis, respectively. Although CAN inhibited protein synthesis in both cancer cells and normal human fibroblasts, it induced eIF2alpha phosphorylation and apoptosis only in cancer cells.
CONCLUSIONS: CAN triggers PKR/eIF2alpha/caspase 12-dependent apoptosis and inhibits protein synthesis in cancer cells but only inhibits protein synthesis in normal cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728285      PMCID: PMC2720712          DOI: 10.1093/jnci/djn239

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  43 in total

Review 1.  The ribotoxic stress response as a potential mechanism for MAP kinase activation in xenobiotic toxicity.

Authors:  Jeffrey D Laskin; Diane E Heck; Debra L Laskin
Journal:  Toxicol Sci       Date:  2002-10       Impact factor: 4.849

Review 2.  Translation initiation in cancer: a novel target for therapy.

Authors:  Funda Meric; Kelly K Hunt
Journal:  Mol Cancer Ther       Date:  2002-09       Impact factor: 6.261

3.  The protein kinase PKR: a molecular clock that sequentially activates survival and death programs.

Authors:  Olivier Donzé; Jing Deng; Joseph Curran; Robert Sladek; Didier Picard; Nahum Sonenberg
Journal:  EMBO J       Date:  2004-01-29       Impact factor: 11.598

4.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta.

Authors:  T Nakagawa; H Zhu; N Morishima; E Li; J Xu; B A Yankner; J Yuan
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

5.  Inhibition of eukaryotic translation initiation by the marine natural product pateamine A.

Authors:  Woon-Kai Low; Yongjun Dang; Tilman Schneider-Poetsch; Zonggao Shi; Nam Song Choi; William C Merrick; Daniel Romo; Jun O Liu
Journal:  Mol Cell       Date:  2005-12-09       Impact factor: 17.970

6.  Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha.

Authors:  Constantinos Koumenis; Christine Naczki; Marianne Koritzinsky; Sally Rastani; Alan Diehl; Nahum Sonenberg; Antonis Koromilas; Bradly G Wouters
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

Review 7.  Does the ribosome translate cancer?

Authors:  Davide Ruggero; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

8.  Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2.

Authors:  Phoebe D Lu; Céline Jousse; Stefan J Marciniak; Yuhong Zhang; Isabel Novoa; Donalyn Scheuner; Randal J Kaufman; David Ron; Heather P Harding
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

9.  The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice.

Authors:  Peichuan Zhang; Barbara C McGrath; Jamie Reinert; DeAnne S Olsen; Li Lei; Sangeeta Gill; Sheree A Wek; Krishna M Vattem; Ronald C Wek; Scot R Kimball; Leonard S Jefferson; Douglas R Cavener
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

10.  Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.

Authors:  Donatella Del Bufalo; Daniela Trisciuoglio; Marco Scarsella; Uwe Zangemeister-Wittke; Gabriella Zupi
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

View more
  18 in total

1.  Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells.

Authors:  Elif Damla Arisan; Zehragül Ergül; Gülnihal Bozdağ; Özge Rencüzoğulları; Ajda Çoker-Gürkan; Pınar Obakan-Yerlikaya; Deniz Coşkun; Narçin Palavan-Ünsal
Journal:  Mol Biol Rep       Date:  2018-11-08       Impact factor: 2.316

2.  Stereochemically versatile synthesis of the C1-C12 fragment of tedanolide C.

Authors:  Thomas E Smith; Sarah J Fink; Zebulon G Levine; Kerani A McClelland; Adrian A Zackheim; Mary E Daub
Journal:  Org Lett       Date:  2012-02-29       Impact factor: 6.005

3.  New candidaspongiolides, tedanolide analogues that selectively inhibit melanoma cell growth.

Authors:  Emily L Whitson; Kristen M Pluchino; Matthew D Hall; James B McMahon; Tawnya C McKee
Journal:  Org Lett       Date:  2011-06-06       Impact factor: 6.005

Review 4.  Natural Marine Products: Anti-Colorectal Cancer In Vitro and In Vivo.

Authors:  Ningning Han; Jianjiang Li; Xia Li
Journal:  Mar Drugs       Date:  2022-05-25       Impact factor: 6.085

Review 5.  Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.

Authors:  Annamaria Rapisarda; Giovanni Melillo
Journal:  Drug Resist Updat       Date:  2009-04-25       Impact factor: 18.500

6.  Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress.

Authors:  Yoshihiro Suzuki; Toshio Inoue; Mayumi Murai; Miki Suzuki-Karasaki; Toyoko Ochiai; Chisei Ra
Journal:  Int J Oncol       Date:  2012-05-17       Impact factor: 5.650

7.  Two new cytotoxic candidaspongiolides from an indonesian sponge.

Authors:  Agus Trianto; Idam Hermawan; Toshimasa Suzuka; Junichi Tanaka
Journal:  ISRN Pharm       Date:  2011-07-18

Review 8.  Recently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment.

Authors:  Magbubah Essack; Vladimir B Bajic; John A C Archer
Journal:  Mar Drugs       Date:  2011-09-20       Impact factor: 6.085

9.  The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer.

Authors:  Yong He; Arlene M Correa; Maria Gabriela Raso; Wayne L Hofstetter; Bingliang Fang; Carmen Behrens; Jack A Roth; Yihong Zhou; Liping Yu; Ignacio I Wistuba; Stephen G Swisher; Apar Pataer
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

10.  A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents.

Authors:  Roberta Bortolozzi; Giampietro Viola; Elena Porcù; Francesca Consolaro; Cristina Marzano; Maura Pellei; Valentina Gandin; Giuseppe Basso
Journal:  Oncotarget       Date:  2014-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.